<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/23EACF04-4313-4CE8-9284-270C62D21BF4"><gtr:id>23EACF04-4313-4CE8-9284-270C62D21BF4</gtr:id><gtr:firstName>Ali</gtr:firstName><gtr:surname>Judd</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/664FA0A0-B6F5-431F-AA4E-4D5070BAD879"><gtr:id>664FA0A0-B6F5-431F-AA4E-4D5070BAD879</gtr:id><gtr:firstName>Kholoud</gtr:firstName><gtr:surname>Porter</gtr:surname><gtr:orcidId>0000-0002-9226-6206</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168CFD16-EA26-4A8A-B3E6-5E11BD817F3E"><gtr:id>168CFD16-EA26-4A8A-B3E6-5E11BD817F3E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Tyre</gtr:otherNames><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122886351"><gtr:id>585F99F5-1E34-46BC-87C4-3510E82C8CCC</gtr:id><gtr:title>HIV Epidemiology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122886351</gtr:grantReference><gtr:abstractText>This is mainly a programme of studies following up adults and children with HIV and fits in well with the clinical trials programme. This is because these studies can highlight areas where more investigative studies like clinical trials need to be done. They are also important in helping statisticians to design these trials and allow us to follow people up over the longer term to see how they do beyond the time that they re in the clinical trials.||The observational studies in adults are the UK Register of HIV Seroconverters, which led to a bigger collaboration called CASCADE funded by the European Commission, and which the UK Register is now part of. CASCADE was first funded in 1997 and brings together experts conducting 23 studies in 15 European countries, Australia and Canada. The studies have one thing in common in that they are of HIV infected people for whom we have a reasonably accurate date of when they became infected, or seroconverted. Information from these seroconverters allow us to follow-up people who ve recently become infected throughout the whole period since they came in contact with the virus.||A study in children called CHIPS (Collaborative HIV Paediatric Study) was established in April 2000, and follows-up HIV infected children in the UK and Ireland. CHIPS is a collaboration between centres caring for HIV-infected children, many of whom are enrolled in PENTA trials (the Paediatric European Network for the Treatment of AIDS), the National Study of HIV in Pregnancy and Childhood (NSHPC) at the Institute of Child Health, and the MRC CTU. The main objectives of CHIPS are to describe clinical, laboratory and treatment data for these children, as well as their use of paediatric HIV services. CHIPS aims to enhance the exchange of information and expertise between centres in order to promote standardised high quality paediatrician-led care of all HIV-infected children in the UK and Ireland.||The UK HIV Drug Resistance Database is a central repository for resistance tests performed as part of routine clinical care throughout the UK. Established in 2001, by the end of 2007 over 51,000 test results have been received and stored. A key feature of the Database is extensive patient-level linkage with several clinical cohorts and surveillance databases in the UK. This has allowed analyses which have given important insights into the epidemiology and clinical aspects of HIV drug resistance.||Evidence for Action (EfA) is a five-year international research programme funded from the UK Department for International Development. EfA focuses on HIV treatment and care systems and the goal of the research programme is to contribute to knowledge on how to design, manage and deliver comprehensive HIV treatment and care programmes in resource-poor settings. The programme will provide evidence-informed, practical recommendations to policy makers, programme managers and funding agencies on how to maximise the benefits and equity of HIV treatment &amp;amp; care systems in developing countries.</gtr:abstractText><gtr:technicalSummary>The HIV epidemiology programme largely comprises cohort studies and cohort collaborations, in adults and children, and complements the clinical trials programme. These observational studies raise questions which may then be answered by trials and are a necessary resource for trial design and sample size calculations. They also contribute to the assessment of long-term outcomes.||In adults, the UK Register of HIV Seroconverters has formed the basis for an HIV cohort collaboration (CASCADE), first established in 1997 and maintained through several successful EU funding bids, between the investigators of 23 cohorts of persons with well-estimated dates of HIV seroconversion (~20,000 seroconverters). It is currently a network of epidemiologists, statisticians, virologists and clinicians from lead HIV institutions in 15 European countries, Australia and Canada. Seroconverters are enrolled into the individual cohorts locally and nationally and are typically followed up life-long. CASCADEs main aim is to monitor newly infected individuals and those already enrolled in studies, covering the entire duration of HIV infection. The main premise is that through pooling data issues can be addressed, which cannot be reliably addressed from single studies alone.||In children, The Collaborative HIV Paediatric Study (CHIPS) was established in April 2000, and is a multi-centre cohort study of HIV infected children in the UK and Ireland. CHIPS is a collaboration between centres caring for HIV-infected children, many of whom are enrolled in PENTA trials (the Paediatric European Network for the Treatment of AIDS), the National Study of HIV in Pregnancy and Childhood (NSHPC) at the Institute of Child Health, and the MRC CTU. The main objectives of CHIPS are to describe clinical, laboratory and treatment data for these children, as well as their use of paediatric HIV services. CHIPS aims to enhance the exchange of information and expertise between centres in order to promote standardised high quality paediatrician-led care of all HIV-infected children in the UK and Ireland.||The UK HIV Drug Resistance Database is a central repository for resistance tests performed as part of routine clinical care throughout the UK. Established in 2001, by the end of 2008 over 51,000 test results have been received and stored. Most of these (around 90%) are in the form of viral gene sequences. A key feature of the Database is extensive patient-level linkage with several clinical cohorts and surveillance databases in the UK. This has allowed analyses which have given important insights into the epidemiology and clinical aspects of HIV drug resistance.||Evidence for Action (EfA) is a five-year international research programme with core funding from the UK Department for International Development. EfA focuses on HIV treatment and care systems and the goal of the research programme is to contribute to knowledge on how to design, manage and deliver comprehensive HIV treatment and care programmes in resource poor settings. The programme will provide evidence-informed, practical recommendations to policy makers, programme managers and funding agencies on how to maximise the benefits and equity of HIV treatment &amp;amp; care systems in developing countries.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>6828982</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Hopital Bicetre</gtr:department><gtr:description>CASCADE</gtr:description><gtr:id>E52E4562-70CB-40E9-92D2-21728176FD95</gtr:id><gtr:impact>CASCADE is a network of 25 cohorts from Europe, Canada, Australia and Africa with &amp;gt;20,000 HIV-infected individuals, drawn from &amp;gt;300 clinics, with early diagnosis of HIV infection and known time period of HIV seroconversion. The network of experts in the diagnosis, management, and analyses of data from individuals with primary HIV infection, is in a unique position to study the full course of HIV infection using data from these individuals. Furthermore, seroconverters are, by definition, optimally identified and have the best chances of access to treatment. They represent, therefore, the ideal of what may be achieved through early testing and presentation, and set a gold standard against which to compare the outcome of all infected individuals.
CASCADE aims focus on identification of early HIV infection and research questions requiring knowledge of the time of seroconversion. Specifically, the network aims to identify and characterize newly-acquired infection, its contribution to the propagation of the epidemic, and to monitor short and long-term outcome and their determinants, especially in terms of the host, HIV and the relationship between the two.</gtr:impact><gtr:outcomeId>puf9hdGytPY-1</gtr:outcomeId><gtr:partnerContribution>Publications and securing FP7 funding</gtr:partnerContribution><gtr:piContribution>Kholoud Porter is Project Leader and will also lead a new FP7-funded Network of Excellence, which will incorporate CASCADE as well as all other HIV European cohorts, from 1st January 2011</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK HIV Drug Resistance Database</gtr:description><gtr:id>DE20106F-50BC-459E-894F-A1FEF4D58DC8</gtr:id><gtr:impact>Multiple papers on HIV drug resistance (surveillance of transmitted drug resistance, molecular epidemiology, clinical aspects)</gtr:impact><gtr:outcomeId>F34B319F468-1</gtr:outcomeId><gtr:partnerContribution>The collaboration is the basis for the researchadvancing knowledge in HIV drug rseistance</gtr:partnerContribution><gtr:piContribution>Lead the collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DHICE</gtr:description><gtr:id>3ABA4D1B-3D48-423B-A321-98889E0F743F</gtr:id><gtr:impact>Enhancing use of patient electronic data for HIV clinical research</gtr:impact><gtr:outcomeId>casP9UCFumi-1</gtr:outcomeId><gtr:partnerContribution>Collaboration is the basis for the research</gtr:partnerContribution><gtr:piContribution>MRC is beneficiary</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EuroCoord NoE</gtr:description><gtr:id>72CA7C10-45A5-4E3A-8BB1-A408F920E8AE</gtr:id><gtr:impact>The following guidelines:
US Department of Health and Human Services- Treatment of adults and adolescents, and perinatal with HIV, and prevention and treatment of opportunistic infections
WHO- Consolidated HIV treatment and prevention guidelines 
International AIDS Society- Adult HIV treatment guidelines, and HIV drug resistance testing
British HIV Association- HIV treatment guidelines, management of Hepatitis viruses, HIV routine investigation and monitoring, and treatment of opportunistics infections
This is a multi-disciplinary collaboration: clinical, epidemiology, statistics, virology, immunology, genetics, public health, bio-informatics, IT</gtr:impact><gtr:outcomeId>smkUDuKFGwc-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data, resources and know-how</gtr:partnerContribution><gtr:piContribution>MRC CTU is Project Lead</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Medical Molecular Virology</gtr:department><gtr:description>CHAIN</gtr:description><gtr:id>84B38CDD-EB3C-40E9-95AA-3CF612F3FD00</gtr:id><gtr:impact>several publications</gtr:impact><gtr:outcomeId>QXrDLKz2Y6b-1</gtr:outcomeId><gtr:partnerContribution>Networking</gtr:partnerContribution><gtr:piContribution>MRC is a beneficairy and is a major contribution to 3 work packages</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cotrimoxazole Prophylaxis Policy Group. Identifying and minimising the gap between knowledge, policy and practice in relation to the use of Cotrimoxazole prophylaxis in adult and paediatric HIV care. XVII International AIDS Conference Mexico City</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>2027D577-B652-4708-9AED-304B744E4E7B</gtr:id><gtr:impact>The paper highlighted the gap between research findings and implementation into policy and practice. The example used is the use of Cotrimoxazole as prophylaxis for HIV infected adults and children in developing countries- although clear evidence known for some time, and low cost, governments and policy makers have been slow to implement.

None at present</gtr:impact><gtr:outcomeId>ACE52A1819A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK HIV Drug Resistance Database</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F6389BA9-C541-4425-87B2-AAB2260B4C28</gtr:id><gtr:impact>many questions

x</gtr:impact><gtr:outcomeId>ovfyeR3G5jP</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Evaluating outcome indicators used to assess the performance of HIV programmes of treatment and care in resource-limited countries. XVII International AIDS Conference Mexico City</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>A4525E45-7E4E-4744-8274-F23D2DB91C64</gtr:id><gtr:impact>The paper argued for the need of an evaluation of indicators used to monitor the success of HIV treatment and care programmes in resource-limited countries as a direct assessment of survival and HIV drug resistance within these programmes is problematic and the indicators used as proxy measures to monitor these outcomes have not been evaluated programmatically

A meeting with the Global Fund to evaluate funding project is set for February 2010</gtr:impact><gtr:outcomeId>5A736B5FD57</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2226000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>026C6320-DE3A-4B42-B976-03723A374EEE</gtr:id><gtr:outcomeId>1C7BA9772CE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2125277</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK HIV Drug Resistance Database</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>63A42E72-CC0C-41D2-BDFD-56D6583895F9</gtr:id><gtr:outcomeId>5460afb99ea3a6.76971339</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>427826</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EUROCOORD (12m euros across 23 participants)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>10762981-8473-40D8-8F35-34F3FBC4A9FE</gtr:id><gtr:outcomeId>10E847AAF7B0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1023000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0D7C5E96-70FB-4436-996E-C644866BCB66</gtr:id><gtr:outcomeId>076D16ADA1A0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1571500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EC FP7</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>E4AA0C5F-49D4-4527-B112-EA82C38F4EBF</gtr:id><gtr:outcomeId>iMx14Bn65dr0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Union DG Sanco</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>F8292443-DCAD-4C4D-B993-48954E54B049</gtr:id><gtr:outcomeId>C8F882D4EA50</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55760</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASCADE (1.7m euros across 25 participants)</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4840364C-6BAC-4C7D-B0AC-B9DC2EB7C6DD</gtr:id><gtr:outcomeId>7FEC784BE0D0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3749247</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>DFID, Project Grant</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:id>2EC3CE40-6F0A-41BE-8FE5-9CE2E0035969</gtr:id><gtr:outcomeId>1DC9EB041090</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>341601</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHAIN Collaborative HIV and Anti-HIV Drug Resistance Network (10m euros across 24 participants)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>D85EE0D4-7D32-40B3-A6A8-7A704BA300F9</gtr:id><gtr:outcomeId>EBA9AB8168D0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>858000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2009-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9A2AA19B-FE4D-4898-B417-6AFBF1505138</gtr:id><gtr:outcomeId>EB65689D3D50</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DoH project grant/UK Department of Health</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>E36CFAAC-B143-4389-99AF-D58CF74B86F4</gtr:id><gtr:outcomeId>hBnZJtb9mmF0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HIV/AIDS Think Tank forum</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>A152E74B-8225-4B53-8B1A-78D7C1E64F32</gtr:id><gtr:impact>Dr Porter was invited to give a presentation at the forum</gtr:impact><gtr:outcomeId>MoHRMf7nubW</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE HBV Appraisal Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>08F38BEA-8329-47C0-93F5-7B92C12B9FB9</gtr:id><gtr:impact>Dr Dunn was part of the review board of Adefovir dipivoxil and pegylated interferon alpha-2a for the treatment of chronic hepatitis B; Recommendation of use in hepatitis B infection</gtr:impact><gtr:outcomeId>7583B84BEF3</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE HCV Appraisal Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>AB4C8657-7721-4B2E-87BF-2DB158578F57</gtr:id><gtr:impact>Expanded indications for treatment of HCV</gtr:impact><gtr:outcomeId>TTXWBKC4iQX</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Conference on poverty-related diseases</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>A2258884-42F5-4241-8305-8ACB65D3AA55</gtr:id><gtr:impact>Dr Porter was invited to present at the conference</gtr:impact><gtr:outcomeId>gybup3vkUrX</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO paediatric HIV guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>9DD9B5EC-CF1D-48A0-A6A8-104B7731B388</gtr:id><gtr:impact>Has affected international/national guidelines</gtr:impact><gtr:outcomeId>F7051AAD341</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EMEA Biotechnology working party</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>99B525EA-BAB1-44BA-BADB-A2D84A605E87</gtr:id><gtr:impact>Dr Porter is the UK Representative on the Biotechnology Working Party Epidemiology Group for the European Agency for the Evaluation of Medicinal Products (EMEA); recommendations for the use of plasmapheresis from companies in countries recently joining the EU</gtr:impact><gtr:outcomeId>8B0A2D0F037</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Incidence Working Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B51055B9-17A6-4CD3-AC66-E2ADBD130662</gtr:id><gtr:impact>Dr Porter was invited to present to the working group</gtr:impact><gtr:outcomeId>CBaVwUgCMTN</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Published in Statistics In Medicine (PubMed ID 19768690)</gtr:description><gtr:id>622E5EA6-4205-401D-B407-30D049E1D35B</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>807B4D32363</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Modelling the association between patient characteristics and the change over</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A practical guide on modelling competing risks data has been prepared and made freely available on the CASCADE website (www.cascade-collaboration.org) for download. The guide briefly introduces the different theoretical approaches to model competing risks data, and focuses on cause-specific and cumulative incidence models, describing their implementation in widely used statistical software (i.e., Stata and/or R). Guidelines on downloading R (free software) and its relevant modules are provided in the appendix. Additionally, the different methods to treat time to a competing event are compared and discussed using examples from the CASCADE database</gtr:description><gtr:id>CAE30CB2-554A-4088-9CE3-0DB90294EDE9</gtr:id><gtr:impact>The guide is being used by statisticians and epudemiologists within the CASCADE Collaboration for analysing longitudinal data in the presence of competing risks (e.g. AIDS events and death)</gtr:impact><gtr:outcomeId>43B1675E0C3</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Competing risks practical guide</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:url>http://www.cascade-collaboration.org</gtr:url><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E5C16CE7-B86A-4C39-8613-33912C1933D7</gtr:id><gtr:title>Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e24cf61836ef00a6a7a928569727da58"><gtr:id>e24cf61836ef00a6a7a928569727da58</gtr:id><gtr:otherNames>Brown AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>AF5BCFB439C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>376BFBF5-A78A-49A3-8616-15DD7B9CABE7</gtr:id><gtr:title>Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a4062466f813286e6d8eb6ab0ea1581"><gtr:id>1a4062466f813286e6d8eb6ab0ea1581</gtr:id><gtr:otherNames>L'homme RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>79852873160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC0E8B7D-4EBA-4F1E-AFBA-3B19A00990C0</gtr:id><gtr:title>HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b0e0090ceccbbd7fd17b20da7528b7"><gtr:id>47b0e0090ceccbbd7fd17b20da7528b7</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (CHIC) Study Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>3C8355B1722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF3CEDF1-FD0F-4819-8921-77DD28E39FE9</gtr:id><gtr:title>Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71c6e0e4266b25f71757f1793eb22db"><gtr:id>f71c6e0e4266b25f71757f1793eb22db</gtr:id><gtr:otherNames>Burns Sheila</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a3606180c7d02.57696410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49DC629-CE0A-46BD-8724-24A2C9441C09</gtr:id><gtr:title>Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8352078ca98c41558105c7dc74704bb4"><gtr:id>8352078ca98c41558105c7dc74704bb4</gtr:id><gtr:otherNames>Pantazis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13071_21_22412867</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96920400-E3EE-46B1-A169-743D986110D9</gtr:id><gtr:title>The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/743184f900cf7f05341330efd5ab8b02"><gtr:id>743184f900cf7f05341330efd5ab8b02</gtr:id><gtr:otherNames>Donegan KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_13071_21_22300840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0BD6655-93AA-4A63-BDC6-297128C98A49</gtr:id><gtr:title>Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>E4WaUDgNbyS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D6EDBA8-9A80-429F-9F8D-0C55A88CE2C4</gtr:id><gtr:title>Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/faeec2c9119a203a37ee815573a04a7f"><gtr:id>faeec2c9119a203a37ee815573a04a7f</gtr:id><gtr:otherNames>van der Helm J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_13071_21_23266560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E295B87-8090-4F87-88B6-345F21392FEC</gtr:id><gtr:title>Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e12855d71fdc2d5fc535bbdad91eb8c7"><gtr:id>e12855d71fdc2d5fc535bbdad91eb8c7</gtr:id><gtr:otherNames>Zugna D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_13071_21_22910338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C2558F7-7D48-433D-B968-9667BF9568AD</gtr:id><gtr:title>Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5cc7c98c8ac1a0cc6c63cc1a5480087"><gtr:id>f5cc7c98c8ac1a0cc6c63cc1a5480087</gtr:id><gtr:otherNames>Lampe FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>1A4603521F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0C20C94-A55F-40AC-8E8C-00C45D362822</gtr:id><gtr:title>Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>TsAaDxuAqZ6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0D5EED0-6458-48F2-A9D0-490BFAD5028E</gtr:id><gtr:title>Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>g7Rmt86mn4k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B8B87D9-4185-461E-9683-10176AFCB0B2</gtr:id><gtr:title>Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dce5a78a3a3902abda3b00e1cd215ac"><gtr:id>7dce5a78a3a3902abda3b00e1cd215ac</gtr:id><gtr:otherNames>HIV Paediatric Prognostic Markers Collaborative Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>C9DF59BA9B8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>336BC480-3F19-4C9E-834C-2061C95B1144</gtr:id><gtr:title>Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35559fb783c85c89aeffc68a0c2d55af"><gtr:id>35559fb783c85c89aeffc68a0c2d55af</gtr:id><gtr:otherNames>Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>maZ6dDw41wR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62C323FC-FE8C-401A-B822-C97CFB3B9839</gtr:id><gtr:title>Response to combination antiretroviral therapy: variation by age.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d93c3705563a63508cbc695a152a149"><gtr:id>0d93c3705563a63508cbc695a152a149</gtr:id><gtr:otherNames>Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>3E371CC0357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A39B8102-C87A-41E3-851D-29D3A4ABB181</gtr:id><gtr:title>Virological response to initial antiretroviral regimens containing abacavir or tenofovir.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>759C252F6A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CD72038-FE30-45A0-BDEB-ED946837F23A</gtr:id><gtr:title>Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/154626858cc42f66f33a93cb72762480"><gtr:id>154626858cc42f66f33a93cb72762480</gtr:id><gtr:otherNames>Garvey L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>imt1ed7pjRm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90775427-F5E0-4A60-B8D1-535E5581226A</gtr:id><gtr:title>Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f57a80aa717e9c41b112e507dcd8ea74"><gtr:id>f57a80aa717e9c41b112e507dcd8ea74</gtr:id><gtr:otherNames>Gompels M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_13071_21_22279171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C0CDB2B-D2CE-421F-8B2F-B07D7780EC37</gtr:id><gtr:title>Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49f7ef523fb0f452490b47c3ea62ed37"><gtr:id>49f7ef523fb0f452490b47c3ea62ed37</gtr:id><gtr:otherNames>Dunn D. T.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a36043576ea29.54642234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A799D48-105E-4142-BD77-4C9CC1992543</gtr:id><gtr:title>Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1bd0cf765f643f4aeca480fd4dbde9c"><gtr:id>b1bd0cf765f643f4aeca480fd4dbde9c</gtr:id><gtr:otherNames>Goetghebuer T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>ECEC177194F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>363D27B3-6FCB-4735-BD32-561A27214845</gtr:id><gtr:title>The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d40f983c26b14cc725a711fb9036e4d"><gtr:id>5d40f983c26b14cc725a711fb9036e4d</gtr:id><gtr:otherNames>Arenas-Pinto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>0E478469DA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75CB51F1-A74C-46BB-BD23-071C95A70C21</gtr:id><gtr:title>Is 1 alanine transaminase &amp;gt;200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>0661CDD0499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC22197D-D5A1-420C-B88E-349ADFAC8A35</gtr:id><gtr:title>Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31232761f545a0b4f18b83b6d054f887"><gtr:id>31232761f545a0b4f18b83b6d054f887</gtr:id><gtr:otherNames>Dorrucci M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>3F8399353AB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62DE2510-8D5F-4FF1-97FD-EEC19DA741E6</gtr:id><gtr:title>Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f9f2f726c29e3ec6d0a6d004eec899b"><gtr:id>0f9f2f726c29e3ec6d0a6d004eec899b</gtr:id><gtr:otherNames>Porter K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>FFB818785F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>207BF89A-87BC-44D5-9D89-E37951C5FC55</gtr:id><gtr:title>Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0c1b39da8809fe4f563fda5119481a"><gtr:id>2d0c1b39da8809fe4f563fda5119481a</gtr:id><gtr:otherNames>Wolbers M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>KKwRgvJ58JM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAA45F2D-9391-40C3-926F-7FF3BFF06B11</gtr:id><gtr:title>Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).</gtr:title><gtr:parentPublicationTitle>The open AIDS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5ceba5b2df1153e4d33c5074278ccb4"><gtr:id>c5ceba5b2df1153e4d33c5074278ccb4</gtr:id><gtr:otherNames>Guiguet M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>51C2CE3398B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFAB972F-D0DA-45C6-8CA7-8917E3DB88A2</gtr:id><gtr:title>Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c30723062483d637e0ebc9fff97497"><gtr:id>57c30723062483d637e0ebc9fff97497</gtr:id><gtr:otherNames>Waters L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>eo7nUmSXq5d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F890D64-916B-49E5-9447-67114AC2F7C5</gtr:id><gtr:title>Authors' response to Drs Scourfield, Jackson and Nelson</gtr:title><gtr:parentPublicationTitle>HIV Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c30723062483d637e0ebc9fff97497"><gtr:id>57c30723062483d637e0ebc9fff97497</gtr:id><gtr:otherNames>Waters L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>gv6UcMnuo1U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD89CD4-61DC-4503-AA44-72121EB23507</gtr:id><gtr:title>Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eead0572c403aa4c8386b4a944a025e5"><gtr:id>eead0572c403aa4c8386b4a944a025e5</gtr:id><gtr:otherNames>Pursuing Later Treatment Option II (PLATO II) project team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>Qou5YrAX3RH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FD0AEC6-1737-490D-A04E-E08D6638413C</gtr:id><gtr:title>Late diagnosis in the HAART era: proposed common definitions and associations with mortality.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f61577ce5353e21eebcd751fd76540c9"><gtr:id>f61577ce5353e21eebcd751fd76540c9</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (UK CHIC) Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pR5QKMoAUAv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85819168-6F8A-44C1-8922-089930DE3A16</gtr:id><gtr:title>Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544e2b17cf5db7.95831619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E79A3FC-6529-47BE-8FF8-4C78DF97EB47</gtr:id><gtr:title>Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dce5a78a3a3902abda3b00e1cd215ac"><gtr:id>7dce5a78a3a3902abda3b00e1cd215ac</gtr:id><gtr:otherNames>HIV Paediatric Prognostic Markers Collaborative Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>YTny5wy3DLn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33BFDB23-9526-4805-9F49-3748BEE2E65C</gtr:id><gtr:title>Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8ddf4eb8bd657dafa0f77c1c74dd383"><gtr:id>c8ddf4eb8bd657dafa0f77c1c74dd383</gtr:id><gtr:otherNames>United Kingdom Collaborative HIV Cohort Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>500E8C04A8A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A181D8E-4A21-494E-AF3B-16F6DB4B4CEF</gtr:id><gtr:title>Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>VGFzY87FvQn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00B1BD28-B9EB-4E4D-93CB-195F73E49ABD</gtr:id><gtr:title>Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>ACFD4C2D882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E851AB1-CA4E-4CD9-945B-76ED64B366FC</gtr:id><gtr:title>HIV diagnosis at CD4 count above 500 Cells/mm(3) and progression to below 350 Cells/mm(3) without Antiretroviral therapy</gtr:title><gtr:parentPublicationTitle>JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd35787cdf0b91e7593902cfa818ce92"><gtr:id>dd35787cdf0b91e7593902cfa818ce92</gtr:id><gtr:otherNames>Phillips Andrew N.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5a3603e3e18a58.74395878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE6C40FF-6D30-4DC7-8E84-5AE00F60BE3E</gtr:id><gtr:title>Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dbb3dd0257d0e5784d379e6c4e36ee4"><gtr:id>1dbb3dd0257d0e5784d379e6c4e36ee4</gtr:id><gtr:otherNames>Mihailidis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>2F2C337ED74</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2600F458-B7C3-4016-B331-DDE7DF5214CE</gtr:id><gtr:title>Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8efaa8f6d6151a6d187dd2dd92e18b9"><gtr:id>b8efaa8f6d6151a6d187dd2dd92e18b9</gtr:id><gtr:otherNames>Touloumi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_13071_21_23223594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55324429-3E36-4BE9-8296-84A38D663467</gtr:id><gtr:title>Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/973358ca2dd8d50a8c229bf5eb150859"><gtr:id>973358ca2dd8d50a8c229bf5eb150859</gtr:id><gtr:otherNames>Gifford RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D2C7F14FB13</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B368F03-D9C2-4E69-8E1D-3A1C273E66C4</gtr:id><gtr:title>Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d1396d74a918505a05f673b969ab05"><gtr:id>a5d1396d74a918505a05f673b969ab05</gtr:id><gtr:otherNames>Doerholt K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>2588E6D6B83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A4F3274-062D-4B63-A674-301A66370D9A</gtr:id><gtr:title>Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.</gtr:title><gtr:parentPublicationTitle>Archives of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0983b50572a9f08027713592ed8e9c81"><gtr:id>0983b50572a9f08027713592ed8e9c81</gtr:id><gtr:otherNames>Writing Committee for the CASCADE Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn><gtr:outcomeId>DTxjsk9351Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18BC1B17-ED8D-43FC-85B1-03642DF174FE</gtr:id><gtr:title>Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5b60c9d6571ed0f21f5b78865f5320d"><gtr:id>d5b60c9d6571ed0f21f5b78865f5320d</gtr:id><gtr:otherNames>Gifford R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>6C09B3860A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D3F3694-D639-48AD-B5D3-ED6BE394031D</gtr:id><gtr:title>Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/051cf62d6d905f0304eb0c4d1af8ba2e"><gtr:id>051cf62d6d905f0304eb0c4d1af8ba2e</gtr:id><gtr:otherNames>Lyagoba F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>Rdv9U7u8wJu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A58A94-38F2-4926-AE0A-B0167EBC00FB</gtr:id><gtr:title>Transmission network parameters estimated from HIV sequences for a nationwide epidemic.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3638c60c9ad8106bcb381bad3e3f65da"><gtr:id>3638c60c9ad8106bcb381bad3e3f65da</gtr:id><gtr:otherNames>Leigh Brown AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_13071_21_21921202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3E06F9E-6F72-46F2-9D26-F641025E45F6</gtr:id><gtr:title>Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>c6LG82dkXxy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8D9F82B-BC5A-41CC-BFDE-523706E380C4</gtr:id><gtr:title>Genotypic resistance testing in routine clinical care.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/240e481ef0597cb94a0384928615c218"><gtr:id>240e481ef0597cb94a0384928615c218</gtr:id><gtr:otherNames>Dunn DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>pm_13071_21_21646877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1D05BA5-D2F2-4B5E-BB20-0D4C73FE9689</gtr:id><gtr:title>Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d90882e650eb8a23e2bf5788035224d2"><gtr:id>d90882e650eb8a23e2bf5788035224d2</gtr:id><gtr:otherNames>Benzie AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>430AACE3CF3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A20C4AF-AE20-4285-86C0-D26CA1A04CA5</gtr:id><gtr:title>The impact of HIV drug resistance testing on changes to treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_13071_21_21297420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B1C4837-A692-4A1E-977D-CC7BF977ACF3</gtr:id><gtr:title>High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9ec63e74088d1c42dff5d3e313ecbe8"><gtr:id>e9ec63e74088d1c42dff5d3e313ecbe8</gtr:id><gtr:otherNames>Rosinska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>pm_13071_21_23343475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>044FF79F-830A-473E-A5F1-456522DED38C</gtr:id><gtr:title>Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-na&amp;iuml;ve individuals.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d0e4078101e2913852def3cc79eff29"><gtr:id>0d0e4078101e2913852def3cc79eff29</gtr:id><gtr:otherNames>Hu? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>3114D867359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFE6DFC6-19A7-42AB-ABB9-F9C5CD5173F3</gtr:id><gtr:title>Survival following HIV infection of a cohort followed up from seroconversion in the UK.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54018cfb81d32f3e685bdfda584eb66f"><gtr:id>54018cfb81d32f3e685bdfda584eb66f</gtr:id><gtr:otherNames>Ewings FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>B047EB1384F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BB0A6D8-D27C-4A8B-AA33-466E520833F5</gtr:id><gtr:title>Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/695a4578e393f7e7c4b9cab9bcec3ac3"><gtr:id>695a4578e393f7e7c4b9cab9bcec3ac3</gtr:id><gtr:otherNames>Dolling D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_13071_21_22151684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34450B0B-D70E-4A8E-B552-87D2D8A63F78</gtr:id><gtr:title>Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8efaa8f6d6151a6d187dd2dd92e18b9"><gtr:id>b8efaa8f6d6151a6d187dd2dd92e18b9</gtr:id><gtr:otherNames>Touloumi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13071_21_23936260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EC943F0-F1B0-436E-9B4F-93561092D9C3</gtr:id><gtr:title>CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>9F1731FBBEA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87DA9B2E-44A5-45A1-832A-D4E081E567B0</gtr:id><gtr:title>Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d88fa4100befde6b7efde177463c25b"><gtr:id>6d88fa4100befde6b7efde177463c25b</gtr:id><gtr:otherNames>Zanchetta M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>6BD938D47CD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6729817F-241E-4797-BD69-63AED3DF20DB</gtr:id><gtr:title>Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>2B80DF24D7F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EDC6201-79CA-4A7F-85F8-999C17258D4F</gtr:id><gtr:title>The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afdf783165c02c37a71e5e1baef67b12"><gtr:id>afdf783165c02c37a71e5e1baef67b12</gtr:id><gtr:otherNames>Turner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>rD83ByG4gxF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6324FCB-1C2D-41A6-BB84-74FB63120A70</gtr:id><gtr:title>Changes in the risk of death after HIV seroconversion compared with mortality in the general population.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51b27dff90b7776e265d03044cb6699d"><gtr:id>51b27dff90b7776e265d03044cb6699d</gtr:id><gtr:otherNames>Bhaskaran K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>9EB1DF4BD3B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>805B2EBF-5FBB-497B-9173-7D55FE37930B</gtr:id><gtr:title>Factors influencing lopinavir and atazanavir plasma concentration.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>0BF6393AA0C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4E67226-A8E4-4492-A017-E98B5DC009B8</gtr:id><gtr:title>Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply.</gtr:title><gtr:parentPublicationTitle>JAMA internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f9f2f726c29e3ec6d0a6d004eec899b"><gtr:id>0f9f2f726c29e3ec6d0a6d004eec899b</gtr:id><gtr:otherNames>Porter K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6106</gtr:issn><gtr:outcomeId>pm_13071_21_23529555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CA48033-D1EA-42C9-9462-EE85240F64E8</gtr:id><gtr:title>Data linkage reduces loss to follow-up in an observational HIV cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/714c11cae3bdf9319cae1a059307588e"><gtr:id>714c11cae3bdf9319cae1a059307588e</gtr:id><gtr:otherNames>Hill T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>pm_13071_21_20347263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ED104B8-8134-4CD6-B953-E445037D538F</gtr:id><gtr:title>What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/702db0aeed63393b610817f5ce6d8df1"><gtr:id>702db0aeed63393b610817f5ce6d8df1</gtr:id><gtr:otherNames>Grover D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>0FB74933DAD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F7AB582-4999-43D9-92E5-8D0D0CEBD53B</gtr:id><gtr:title>The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68a3b528ff9b1f0d0bddbdf896177d53"><gtr:id>68a3b528ff9b1f0d0bddbdf896177d53</gtr:id><gtr:otherNames>Green H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>E783F039EA7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B2F4FA8-DEFE-4B45-8C70-40BABFB6AF61</gtr:id><gtr:title>Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/801b89bcbbadfe35293e42012e24ca43"><gtr:id>801b89bcbbadfe35293e42012e24ca43</gtr:id><gtr:otherNames>Barber TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_13071_21_22258921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77EFE761-FAF7-4C7B-95B7-C10B89E04EC6</gtr:id><gtr:title>The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>PRqzPPLWQF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B3BF510-7141-495E-BFDA-CDE88A6551AE</gtr:id><gtr:title>Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>418C20FBE99</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DBE3F75-87AC-4075-949D-E8B755B063CE</gtr:id><gtr:title>Non-uptake of highly active antiretroviral therapy among patients with a CD4 count &amp;lt; 350 cells/?L in the UK.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64fa8c17b9aa548557c762139ce65be3"><gtr:id>64fa8c17b9aa548557c762139ce65be3</gtr:id><gtr:otherNames>Kober C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_13071_21_22106827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7386E76-80FF-4FB2-A7EF-A16E446B8CBC</gtr:id><gtr:title>Decline of CD4? T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21635c26d64629e5278fa0599226a2bc"><gtr:id>21635c26d64629e5278fa0599226a2bc</gtr:id><gtr:otherNames>Mussini C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>Zb6BQSLwuaB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB08D785-E46D-44BC-A7D2-3206EECF41BA</gtr:id><gtr:title>Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2829bf40f2ead8322cd3febe3403c183"><gtr:id>2829bf40f2ead8322cd3febe3403c183</gtr:id><gtr:otherNames>Achhra AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_13071_21_22614887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54A79652-A8B3-4D78-B9A0-5DEB09228859</gtr:id><gtr:title>Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>1B3FF734DF0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E54B88AC-699B-4148-A3D8-1156ABD0849E</gtr:id><gtr:title>Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51b27dff90b7776e265d03044cb6699d"><gtr:id>51b27dff90b7776e265d03044cb6699d</gtr:id><gtr:otherNames>Bhaskaran K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>775AB8021C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F5900C1-CFF9-487D-B7A2-C36A16B7A9EF</gtr:id><gtr:title>Natural history of HIV-control since seroconversion.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e0981385f9ed651683ac74a8c32eb9"><gtr:id>34e0981385f9ed651683ac74a8c32eb9</gtr:id><gtr:otherNames>Madec Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_13071_21_23912979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB172C7-1A2B-4593-9A02-3D9FE3EAE253</gtr:id><gtr:title>Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a90b45f679d889fd75b95b5af0f57380"><gtr:id>a90b45f679d889fd75b95b5af0f57380</gtr:id><gtr:otherNames>Wittkop L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>KnuHtk3wK7o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6922FBE8-2A03-42ED-8E03-58546F90B4F7</gtr:id><gtr:title>Late presenters in an HIV surveillance system in Italy during the period 1992-2006.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b825ab4fc6e6fcdae5b7923c3219c3d1"><gtr:id>b825ab4fc6e6fcdae5b7923c3219c3d1</gtr:id><gtr:otherNames>Borghi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>0AB932A7039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B93E636A-7194-471C-9749-F85F9B59085A</gtr:id><gtr:title>Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>EE880C28FBC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C87B9A55-A84A-497B-A146-AD455CCA9953</gtr:id><gtr:title>Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d885051a227dbae6e97a5dd0099cd5a"><gtr:id>1d885051a227dbae6e97a5dd0099cd5a</gtr:id><gtr:otherNames>Smit C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>E2DEDFB3D4C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A801192B-FB4E-4D0A-978A-C7AFE040EBEE</gtr:id><gtr:title>Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bfd7cf3d8aacf5a4a193b1e91e7ea59"><gtr:id>1bfd7cf3d8aacf5a4a193b1e91e7ea59</gtr:id><gtr:otherNames>Phillips A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>23103504BAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C94E22F0-384C-4BB7-96E6-BA909A5BC8A7</gtr:id><gtr:title>Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.</gtr:title><gtr:parentPublicationTitle>Archives of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn><gtr:outcomeId>pm_13071_21_22826124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13C5EF32-2A63-42DC-AD33-E42B450C3756</gtr:id><gtr:title>Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46286eef88a09fac06d9580bfa9a952e"><gtr:id>46286eef88a09fac06d9580bfa9a952e</gtr:id><gtr:otherNames>Gilson RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>YbbD9Bjce4z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A81AD8AE-E5DB-4722-BA75-0ACA8711831D</gtr:id><gtr:title>Adipogenic gene variants in patients with HIV-associated lipodystrophy.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_13071_21_21178827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B4F76DD-4412-4731-B74F-D70C57CC64C2</gtr:id><gtr:title>Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds &amp;lt;200, &amp;lt;350, and &amp;lt;500 Cells/mm&amp;sup3;: assessment of need following changes in treatment guidelines.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>Nru5BsGTXfS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D5484E8-CD1A-4A2A-BE12-685545E6810F</gtr:id><gtr:title>Antiretroviral treatment of primary HIV infection to reduce onward transmission.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>b92Gz5cHfFj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9C7BFFC-19AA-44A3-861D-6C7A2EBE7D9C</gtr:id><gtr:title>Risk of tuberculosis following HIV seroconversion in high-income countries.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_13071_21_23117980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56A109A3-5CF2-4D07-AA3A-57FBF2306982</gtr:id><gtr:title>When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>miAHUvG4eg5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62FB988C-0B2B-4964-9EB0-2AC84186A1FA</gtr:id><gtr:title>Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/061981b83e8b7d1055ec8ea525737650"><gtr:id>061981b83e8b7d1055ec8ea525737650</gtr:id><gtr:otherNames>Jarrin I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>4C5B3997399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BD62645-758F-4105-A8C3-B810CB16AD0E</gtr:id><gtr:title>Molecular epidemiology of recent HIV-1 infections in southern Poland.</gtr:title><gtr:parentPublicationTitle>Journal of medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/293a73d619593f350bbc45dd25a80fdf"><gtr:id>293a73d619593f350bbc45dd25a80fdf</gtr:id><gtr:otherNames>Smolen-Dzirba J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0146-6615</gtr:issn><gtr:outcomeId>pm_13071_21_23080488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51633DEE-64ED-4FD4-9266-025F6C696A1D</gtr:id><gtr:title>Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0adb6e1e21482905a8463debdc02a98e"><gtr:id>0adb6e1e21482905a8463debdc02a98e</gtr:id><gtr:otherNames>Lee KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>565D541F09C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>446A3917-DE78-4025-BEBC-C86770D93831</gtr:id><gtr:title>Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>qvfC85KYgnH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91A7DDA6-6604-4ADF-8819-EF2ED79FF9D7</gtr:id><gtr:title>Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8efaa8f6d6151a6d187dd2dd92e18b9"><gtr:id>b8efaa8f6d6151a6d187dd2dd92e18b9</gtr:id><gtr:otherNames>Touloumi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>06EFAEFA388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5881AD99-C2E1-4C29-90E2-B330694F037A</gtr:id><gtr:title>Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d40f983c26b14cc725a711fb9036e4d"><gtr:id>5d40f983c26b14cc725a711fb9036e4d</gtr:id><gtr:otherNames>Arenas-Pinto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_13071_21_21447871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>840E50F0-A7FD-4D11-8B2F-78C4FE1B6360</gtr:id><gtr:title>CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>Ua2USakFPdh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AB19631-B985-45BC-A758-BCBC86124CCD</gtr:id><gtr:title>Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/807907210ceade90d704265bbc5bc924"><gtr:id>807907210ceade90d704265bbc5bc924</gtr:id><gtr:otherNames>Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>102CDD387A0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB7DD883-930C-4311-AA08-4F7ECC44F6AA</gtr:id><gtr:title>Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24458c08d0d487d652c1a2bfe83e59bc"><gtr:id>24458c08d0d487d652c1a2bfe83e59bc</gtr:id><gtr:otherNames>Kekitiinwa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>1EAA92F0117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7153E220-1C2F-4BDC-9D8B-4C98DDBE14CE</gtr:id><gtr:title>The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88ca6a744cb967e6309c7f6a5e6afe4e"><gtr:id>88ca6a744cb967e6309c7f6a5e6afe4e</gtr:id><gtr:otherNames>van der Helm JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>YwuxGXBfe42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21D10E0B-9D24-48BA-AE4A-56BF0CD0C422</gtr:id><gtr:title>Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c64cabb2f672b4d549d1ca9b6d5848d0"><gtr:id>c64cabb2f672b4d549d1ca9b6d5848d0</gtr:id><gtr:otherNames>Bezemer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>C480F72B9AB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D12D0D5-9E7E-44C4-B52D-BE28609D63E9</gtr:id><gtr:title>Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b18ef1bb71f9d1c5b2422991e2bebc17"><gtr:id>b18ef1bb71f9d1c5b2422991e2bebc17</gtr:id><gtr:otherNames>Hughes RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_13071_21_21569188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1780B0D-6BCA-449C-95C0-DAF9AFF88511</gtr:id><gtr:title>The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>RFCuL46xRgR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A643A4E3-8794-4CDA-8361-7FF7A40B4825</gtr:id><gtr:title>Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f922cffe072fd13496e024ca3b4ee31f"><gtr:id>f922cffe072fd13496e024ca3b4ee31f</gtr:id><gtr:otherNames>Castro H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_13071_21_22416878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EB1797B-7769-44E0-BFC4-C6889A3721A0</gtr:id><gtr:title>Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b95a761fbb6944bf0ea328da723353f"><gtr:id>7b95a761fbb6944bf0ea328da723353f</gtr:id><gtr:otherNames>Menson EN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>A7E879CE3E7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C38DA6B-1C2A-4D9B-8E7B-86DE3BB25331</gtr:id><gtr:title>Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/240e481ef0597cb94a0384928615c218"><gtr:id>240e481ef0597cb94a0384928615c218</gtr:id><gtr:otherNames>Dunn DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_13071_21_21768516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02BDE9FF-9CFC-4850-A505-557104CD8406</gtr:id><gtr:title>Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c2dc3cb91c8d7e7089e83ba9820a2f"><gtr:id>03c2dc3cb91c8d7e7089e83ba9820a2f</gtr:id><gtr:otherNames>Bansi LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>BD936BA7AF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD606B80-C1B5-4BAD-8590-C284C3408D4A</gtr:id><gtr:title>HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0efa7d2c265a7c0d011f8d7592dd5d"><gtr:id>fd0efa7d2c265a7c0d011f8d7592dd5d</gtr:id><gtr:otherNames>Chakraborty R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>5F206FD7273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54144CC5-334E-49E1-9161-30FFE020E94C</gtr:id><gtr:title>Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>B7C3E388BB1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>054F88B3-593C-4524-91F6-CDC7FA19DD44</gtr:id><gtr:title>Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience</gtr:title><gtr:parentPublicationTitle>Clinical Investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/676231844dc4b6a0e340b3b49cabb12a"><gtr:id>676231844dc4b6a0e340b3b49cabb12a</gtr:id><gtr:otherNames>de Wolf F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>MmNvz3H5jxi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65EA245E-C61C-4C5A-B92D-0E1402B06F99</gtr:id><gtr:title>Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8efaa8f6d6151a6d187dd2dd92e18b9"><gtr:id>b8efaa8f6d6151a6d187dd2dd92e18b9</gtr:id><gtr:otherNames>Touloumi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>640F4FB5FFC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3F8793A-0025-43FF-BA3E-947220BB8B08</gtr:id><gtr:title>Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ecc24f1457bf44eaaa5dec325d1328"><gtr:id>56ecc24f1457bf44eaaa5dec325d1328</gtr:id><gtr:otherNames>Arenas-Pinto A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a351694bd53f6.91207535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D5C934A-9AEA-4CDC-9A49-960A8CA530C8</gtr:id><gtr:title>Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0273dd103e257f1782539313e806d79c"><gtr:id>0273dd103e257f1782539313e806d79c</gtr:id><gtr:otherNames>Cozzi-Lepri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13071_21_22110581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F43E5A0-D36A-4A47-9EA1-A8654A1E78E4</gtr:id><gtr:title>Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58b8564f9b5eee1b537754e2687f762b"><gtr:id>58b8564f9b5eee1b537754e2687f762b</gtr:id><gtr:otherNames>When To Start Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5C2C6AC14C4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BF6A6E3-F2D9-4CC3-A720-EAE574F7A11C</gtr:id><gtr:title>CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda3c874d6e33c2fafcfea247a9eedbe"><gtr:id>cda3c874d6e33c2fafcfea247a9eedbe</gtr:id><gtr:otherNames>Bower M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>E98129405EE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>441619D1-7D6F-4231-B82B-7C48E9BE339F</gtr:id><gtr:title>Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2bb0b05db50d7622ad34646ff7bfe15"><gtr:id>a2bb0b05db50d7622ad34646ff7bfe15</gtr:id><gtr:otherNames>Easterbrook PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>D219D47F39D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>455ACD74-13F3-48CE-AC32-E6F248963649</gtr:id><gtr:title>Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544e2957c429b9.80125565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FECC4458-6627-4D50-B8B8-7F00723EF28F</gtr:id><gtr:title>The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b4f4f0e21733962eec60068490aaae8"><gtr:id>8b4f4f0e21733962eec60068490aaae8</gtr:id><gtr:otherNames>Sabin CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>9C18E887A38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE10FDAD-87CC-409A-B867-5B972B022F89</gtr:id><gtr:title>When it is better to estimate a slope with only one point.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7a7c4dd8930be4515c3adc5f9579ee3"><gtr:id>f7a7c4dd8930be4515c3adc5f9579ee3</gtr:id><gtr:otherNames>Thi?baut R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>eDzbEs1g28E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A06728CA-05C6-452F-BA49-339D98031D98</gtr:id><gtr:title>Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>9E391D764C4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C76A4343-F5B1-4B85-AA3F-22B7C2C44514</gtr:id><gtr:title>Primary HIV infection: to treat or not to treat?</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>A95B5FD688B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C9F9EE7-7E36-4B2D-B20B-F1A2ABCF64B8</gtr:id><gtr:title>The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5802b8e89cc50816134996d592422a4"><gtr:id>e5802b8e89cc50816134996d592422a4</gtr:id><gtr:otherNames>Pillay D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>AA5C9953364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD75F61A-10B1-4178-8913-BF2598897C07</gtr:id><gtr:title>HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b0e0090ceccbbd7fd17b20da7528b7"><gtr:id>47b0e0090ceccbbd7fd17b20da7528b7</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (CHIC) Study Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>bB5RkDJWBx7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D560F17C-17C7-4EAB-8779-808BC5C3A6E3</gtr:id><gtr:title>Management of paediatric HIV-1 resistance.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>1238BEF625C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>412DBA03-F49F-4D81-BCE3-EC17F00A1589</gtr:id><gtr:title>The effect of antiretroviral treatment of different durations in primary HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8352078ca98c41558105c7dc74704bb4"><gtr:id>8352078ca98c41558105c7dc74704bb4</gtr:id><gtr:otherNames>Pantazis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>C5A27F25B6A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3D841D3-8D18-4B20-BFCF-FB266476E5F5</gtr:id><gtr:title>Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f48e17fbd8a0a2d8d5cdceaef1042b6"><gtr:id>9f48e17fbd8a0a2d8d5cdceaef1042b6</gtr:id><gtr:otherNames>Price H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>Ny6rk7jKVJN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32AFD00F-D038-411D-A414-6CE74639F48D</gtr:id><gtr:title>Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.</gtr:title><gtr:parentPublicationTitle>Archives of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13b769a2fb83ff1e7790ea82df90d227"><gtr:id>13b769a2fb83ff1e7790ea82df90d227</gtr:id><gtr:otherNames>Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn><gtr:outcomeId>sjGeQ5NSevs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4435F904-164F-4C6A-BF2B-2B35D0D090B3</gtr:id><gtr:title>Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d4c2f57f6f7c6e7b09cbfa839e2119c"><gtr:id>1d4c2f57f6f7c6e7b09cbfa839e2119c</gtr:id><gtr:otherNames>Geretti AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>E80F701F69C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>380F73FE-477A-4989-83A5-B9FB4636A976</gtr:id><gtr:title>Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_13071_21_22915687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C97EC126-925F-4174-9B50-2990DFEA97DF</gtr:id><gtr:title>Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services.</gtr:title><gtr:parentPublicationTitle>AIDS patient care and STDs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f848550dbe891932000645627591af7c"><gtr:id>f848550dbe891932000645627591af7c</gtr:id><gtr:otherNames>Foster C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1087-2914</gtr:issn><gtr:outcomeId>E03A2EB79C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7054077C-9DAA-4687-9DAC-F7E7A3713E8C</gtr:id><gtr:title>HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f213c1c9e7860c6d84b3dac6b1ef48e3"><gtr:id>f213c1c9e7860c6d84b3dac6b1ef48e3</gtr:id><gtr:otherNames>Chilton DN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>rrJcWrFv8ru</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBEF3256-A584-4585-A77B-78EFDEE1CF18</gtr:id><gtr:title>Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c53934bf9755c630ff0c75bf9a34c8e"><gtr:id>2c53934bf9755c630ff0c75bf9a34c8e</gtr:id><gtr:otherNames>Marin B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>o6bzCrbqs8z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAF15AC8-5E77-494F-BC38-136053582258</gtr:id><gtr:title>Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76c7e7f6d167384202514d2509288582"><gtr:id>76c7e7f6d167384202514d2509288582</gtr:id><gtr:otherNames>Nebbia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>DFCCBB83561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DD3D623-2CE1-436B-82A8-2804DFB5A7EA</gtr:id><gtr:title>Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>B34DA684230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64584539-FA4B-4694-9E75-7D487A3755F2</gtr:id><gtr:title>Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/061981b83e8b7d1055ec8ea525737650"><gtr:id>061981b83e8b7d1055ec8ea525737650</gtr:id><gtr:otherNames>Jarrin I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_13071_21_22109944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3128E556-30C7-4027-AB6D-6F0282C12F4D</gtr:id><gtr:title>Evaluating the systems used to monitor HIV populations accessing therapy and care in low-income and lower-middle-income countries.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50e56361c032477c2f55b7b6038aa672"><gtr:id>50e56361c032477c2f55b7b6038aa672</gtr:id><gtr:otherNames>Hoskins S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_13071_21_23303435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC37F2C4-7939-4ECA-8AF5-68CF40532FD0</gtr:id><gtr:title>Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85a60e5066ab5ec74048e84f9e035c69"><gtr:id>85a60e5066ab5ec74048e84f9e035c69</gtr:id><gtr:otherNames>Grant AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>c7A1D3yjm7o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480A7FF3-1A28-45E0-8C16-66BAE8DE5E73</gtr:id><gtr:title>Children with HIV are not small adults: what is different in pharmacology?</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad756da290788ec7ab09c8d1312b059f"><gtr:id>ad756da290788ec7ab09c8d1312b059f</gtr:id><gtr:otherNames>L'homme R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>BF3B50DA824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF164464-0251-4C3D-B5B4-10F8C859568C</gtr:id><gtr:title>Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f060a7015e50601b1b07aeb4c4fa4fb7"><gtr:id>f060a7015e50601b1b07aeb4c4fa4fb7</gtr:id><gtr:otherNames>Jaffe HW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>QmTepgSCYr7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>647789DF-3F1B-479D-BF31-F543CB62FA81</gtr:id><gtr:title>Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7eaedb1b1fcc1af476a4edafd26c45a4"><gtr:id>7eaedb1b1fcc1af476a4edafd26c45a4</gtr:id><gtr:otherNames>Cane PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>17377F8D653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A42A793-6CE7-4C58-A356-15B52A570542</gtr:id><gtr:title>Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/801b89bcbbadfe35293e42012e24ca43"><gtr:id>801b89bcbbadfe35293e42012e24ca43</gtr:id><gtr:otherNames>Barber TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_13071_21_21900712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2833FAF-38BE-4C2B-B140-7150FB3ADA54</gtr:id><gtr:title>Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d06d65b57027b1d3d31e886a00480e41"><gtr:id>d06d65b57027b1d3d31e886a00480e41</gtr:id><gtr:otherNames>Lactic Acidosis International Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>DA3633B778F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6153A9CC-7156-429C-B2F4-6273378D368A</gtr:id><gtr:title>The impact of the 0-0 cell on measures of amino acid covariation.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>8ABAE65097A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E22873CD-BBC4-4E86-B3CF-CAFAB86798AC</gtr:id><gtr:title>Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22da6316775f98cb557e88c2def5104f"><gtr:id>22da6316775f98cb557e88c2def5104f</gtr:id><gtr:otherNames>Huang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_13071_21_23221982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>319CF17B-FB3E-4914-A763-700382653B6E</gtr:id><gtr:title>Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f848550dbe891932000645627591af7c"><gtr:id>f848550dbe891932000645627591af7c</gtr:id><gtr:otherNames>Foster C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>E2F1A700A85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94E11769-4970-418A-BB1C-A5BB9F67AFBE</gtr:id><gtr:title>Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>3778961EC4F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>136F4DE7-7F7F-4AAA-8CB2-C3A535414FE3</gtr:id><gtr:title>Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73f4417aa699eee44ad518534bfb9b32"><gtr:id>73f4417aa699eee44ad518534bfb9b32</gtr:id><gtr:otherNames>Hughes GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>E2BB7D61454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9D76A70-3E05-4D7D-909A-66860FC80251</gtr:id><gtr:title>Determinants of response to first HAART regimen in antiretroviral-na&amp;iuml;ve patients with an estimated time since HIV seroconversion.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7a7c4dd8930be4515c3adc5f9579ee3"><gtr:id>f7a7c4dd8930be4515c3adc5f9579ee3</gtr:id><gtr:otherNames>Thi?baut R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>qAw4wbd4AGC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>437C54D0-8B8A-4BB8-970A-706EEDDF9C89</gtr:id><gtr:title>An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50e56361c032477c2f55b7b6038aa672"><gtr:id>50e56361c032477c2f55b7b6038aa672</gtr:id><gtr:otherNames>Hoskins S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>NrmtFN7N3GT</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122886351</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>